GLIMDA-MV 2

Description

Glimda-MV 2 Tablet is a fixed-dose combination anti-diabetic medicine from Cipla Ltd that contains Metformin Hydrochloride 500mg, Glimepiride 2mg, and Voglibose 0.2mg per tablet. This triple combination is prescribed for the management of type 2 diabetes mellitus in adults, especially when single or dual therapy does not adequately control blood sugar.

How it Works:

• Metformin: Reduces glucose production in the liver, delays glucose absorption from the intestines, and improves the body’s response to insulin.

• Glimepiride: A sulfonylurea that increases the secretion of insulin from the pancreas, helping cells absorb and use glucose.

• Voglibose: Delays the breakdown and absorption of carbohydrates in the intestine, preventing sharp blood sugar spikes after meals (postprandial glucose control).

By targeting different aspects of glucose control, Glimda-MV 2 provides strong management of both fasting and postprandial blood glucose levels, helping to prevent diabetes-related complications such as kidney damage, retinopathy, neuropathy, and cardiovascular risks.

Uses of Glimda-MV 2:

• Management of type 2 diabetes mellitus in adults

• Control of fasting and post-meal blood glucose levels

• Reduces risk of long-term diabetes complications

Key Benefits:

• Triple action—targets sugar production, utilization, and absorption

• Prevents severe post-meal glucose spikes

• Simplifies diabetes therapy by combining three drugs into one tablet

• Prevents sudden rises in blood glucose

• May assist with weight management and improve overall metabolic health

Dosage & Administration:

• Usual dosage: One tablet daily (specific dosing frequency as advised by your doctor), typically taken with meals to minimize stomach upset

• Swallow whole with water; do not crush or chew

• Take at the same time each day for consistent efficacy

• Continue diet and exercise recommendations for best results

Safety & Precautions:

• Use only on medical prescription

• Monitor blood sugar levels regularly during treatment

• Common side effects: hypoglycemia (especially if meals are missed), nausea, vomiting, stomach pain, diarrhea, dizziness, headache

• Not recommended for patients with type 1 diabetes, diabetic ketoacidosis, or severe kidney/liver disease

• Avoid alcohol during therapy to reduce the risk of side effects

• Dose adjustments may be needed in patients with kidney or liver impairment

• Not to be discontinued abruptly without consulting your doctor

Note:
Consistent monitoring, adherence to diet and exercise, and regular follow-ups are crucial for safe and effective diabetes management with Glimda-MV 2 Tablet.